CDMX · NYC · Cross-Border Biotech
A two-way investment channel between the United States and Mexico — connecting off-market, private U.S. biotech and pharma dealflow with a closed network of LATAM capital, industrial operators, and strategic partners.
The Channel
The conversations that define global biotech happen in rooms in New York, Boston, and San Francisco. Argentina is there. Chile is there. India, Canada, Europe — all there.
Mexico is not at those tables. Yet.
Scirena operates the first structured channel of its kind — connecting Mexican and U.S. capital, scientists, and industrial operators on both sides of the border into private, off-market deal flow that moves in both directions.
Syndicated deal-by-deal through SPVs.
Not a blind pool. Full transparency.
With selective activity across broader Latin America and global markets where strategic alignment exists.
Why Now
Investment Focus
Pre-seed to Series A · Selectively beyond
Leadership
Supported by a network of legal, M&A, and C-suite advisors — biotech executives, pharma operators, and cross-border structuring specialists across the United States and Mexico — engaged deal-by-deal.
Participation is selective. We are not looking for passive capital — we are looking for operators, connectors, and industry leaders who understand that building this channel requires strategic presence, not just financial exposure.
Consulting Services
Supporting biotech and industrial companies in positioning, partnerships, and market access across the U.S.–Latin America corridor.
What We Offer
Who We Work With
Biotech companies, CROs, and technical platforms with strong scientific foundations and clear commercial ambition — particularly those with cross-border relevance between U.S. and Latin American markets.
We work with a limited number of companies at any time. Engagements are selective.
If you're building something technically strong with real commercial potential, submit your materials for consideration.
We work with a limited number of companies.
